Sumitomo Pharma Oncology Presented Preliminary Data From Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients With Myelofibrosis at American Society of Hematology 2022 Annual Meeting & Exposition

February 3, 2023

Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, presented new data from the ongoing Phase 1/2 study evaluating TP-3654, an investigational selective oral PIM1 kinase inhibitor, in patients with myelofibrosis (MF) previously treated with or ineligible for JAK inhibitor therapy at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition, held December 10-13, 2022. Based on preliminary findings from the Phase 1 dose escalation study, TP-3654 appears to be well-tolerated with limited myelosuppressive adverse events. TP-3654, as a single agent, showed preliminary signs of clinical activity in the study, including spleen volume reduction, symptom improvement, and broad cytokine reduction, in patients previously treated with JAK inhibitors. To view the presentation, click here.

“We are pleased by these preliminary clinical data and are encouraged by the safety and tolerability data seen in the ongoing TP-3654 dose escalation study. We remain committed to progressing this program, including expanding our clinical sites, and contributing to the advancement of possible treatment options which may improve outcomes for patients with myelofibrosis,” said Patricia S. Andrews, chief executive officer and global head of oncology, Sumitomo Pharma Oncology, Inc.

TP-3654 is currently being evaluated in a Phase 1/2 study of oral TP-3654 in patients with intermediate and high-risk myelofibrosis, which is being conducted in the United States and Japan. To learn more about the study and eligibility for enrollment, visit clinicaltrials.gov (NCT04176198).